Science – Optimum Strategic Communications

Asceneuron Expands Scientific Advisory Board with World Leading Experts in Neurodegenerative Diseases

6 March 2024/in Client news

Significant appointments of industry and academic experts to support Phase II development of ASN51 in Alzheimer’s disease Lausanne, SWITZERLAND and San Francisco, CA, USA, 6 March 2024 – Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases, today announces the appointments of neurodegenerative disease experts to its Scientific Advisory Board […]

LSX World Congress 2022

13 April 2022/in Insights

Optimum is a proud supporter of LSX. Every year it’s World Congress gathers the founders and CEOs of innovative start-ups through to publicly healthcare giants, and everyone in between.

Merck KGaA, Darmstadt, Germany, Expands Corporate Venture Fund M Ventures with a New Investment of € 600 Million

8 December 2021/in Client news

Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the expansion of its strategic, corporate venture capital arm M Ventures Darmstadt, Germany, December 8, 2021: Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the expansion of its strategic, corporate venture capital arm M Ventures. The new investment of € […]